Tailored for difficult targets, first-in-class targets, and companion diagnostic needs of customers, ACROBiosystems provides IHC antibody development service, solving the problem where commercial antibodies perform poorly or are unavailable for specific targets, specific indications, or specific tissue types, thereby supporting customers’ pathology research, clinical companion diagnostic (CDx) development, and biomarker detection in clinical trials. Full-process antibody customization service from immunogen design to pathology validation, ensuring high specificity, high sensitivity, and feasibility in real tissue samples.
Human Colorectal Cancer (FFPE) – 20x
Human Breast Cancer (FFPE) – 20x
Human Cervical Cancer – 20x